Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Carlos Zamora Atenza"'
Autor:
Leticia Alserawan, Geòrgia Anguera, Carlos Zamora Atenza, Jorgina Serra López, Laura Martínez-Martínez, Mariona Riudavets Melià, Ivana Sullivan, Andrés Barba Joaquin, Margarita Majem Tarruella, Silvia Vidal
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 20, p 12641 (2022)
Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of an
Externí odkaz:
https://doaj.org/article/61f89e0f499e4fbb936319d8bef849fc
Autor:
Rubén Osuna‐Gómez, Silvia Barril, Maria Mulet, Carlos Zamora Atenza, Paloma Millan‐Billi, Ana Pardessus, Douglas E. Brough, Helen Sabzevari, Roshanak T. Semnani, Diego Castillo, Silvia Vidal
Publikováno v:
Immunology. 168:610-621
Pulmonary fibrosis involves various types of immune cells and soluble mediators, including TGF-β and IL-35, a recently identified heterodimeric cytokine that belongs to the IL-12 cytokine family. However, the effect of regulatory IL-35 may play an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::802230165148433efdeacd40c5db8389
https://doi.org/10.1111/imm.13596
https://doi.org/10.1111/imm.13596
Autor:
Carlos Zamora Atenza, Geòrgia Anguera, Mariona Riudavets Melià, Letícia Alserawan De Lamo, Ivana Sullivan, Andrés Barba Joaquin, Jorgina Serra Lopez, M. Angels Ortiz, Maria Mulet, Sílvia Vidal, Margarita Majem
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1823-1835
Tumor PD-L1 expression is a predictive biomarker for patients with NSCLC receiving PD-(L)1 blockade agents. However, although increased tumor PD-L1 expression predicts responsiveness, clinical benefit has been observed regardless of tumor PD-L1 expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a857da021b752dc31cb8a2ed8b18c538
https://doi.org/10.1007/s00262-021-03107-y
https://doi.org/10.1007/s00262-021-03107-y
Autor:
Elisabet Cantó, Esther Garcia Planella, Carlos Zamora-Atenza, Juan Camilo Nieto, Jordi Gordillo, Ma Angels Ortiz, Isidoro Metón, Elena Serrano, Esteban Vegas, Orlando García-Bosch, Cándido Juárez, Sílvia Vidal
Publikováno v:
PLoS ONE, Vol 9, Iss 4, p e93910 (2014)
The exact function of interleukin-19 (IL-19) on immune response is poorly understood. In mice, IL-19 up-regulates TNFα and IL-6 expression and its deficiency increases susceptibility to DSS-induced colitis. In humans, IL-19 favors a Th2 response and
Externí odkaz:
https://doaj.org/article/385015253f4f4b73a045699f04ad175c
Autor:
Lluís Puig, María Teresa Sanz-Martínez, Miguel Angel Sánchez Martínez, Esther Moga, Silvia M. Vidal, Carlos Zamora Atenza, Cándido Juárez
Publikováno v:
The Journal of investigative dermatology. 140(6)
Psoriasis is currently considered to be an immune-mediated disease whose patho-mechanisms involve platelet activation, which seems to correlate with the activity of the disease. Platelet activation is associated with the formation of platelet-lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4215ca4657ca9c54e1c0ab1e73dee4aa
https://pubmed.ncbi.nlm.nih.gov/31778714
https://pubmed.ncbi.nlm.nih.gov/31778714
Autor:
Cándido Juárez, Carlos Zamora-Atenza, Josep Maria Llobet, Patricia Moya, Ivan Castellví, M. Angels Ortiz, Cesar Diaz-Lopez, Carme Geli, Cesar Diaz-Torne, Elisabet Cantó, Silvia Vidal, Juan C. Nieto, Jordi Casademont
Publikováno v:
Arthritis Research & Therapy
Introduction Adalimumab is a fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody that specifically blocks the interaction of TNFα with its receptors. It binds both soluble and transmembrane TNFα. We hypothesized that blocki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc41131d010cc6de1c6414837bfb637
https://pubmed.ncbi.nlm.nih.gov/25037855
https://pubmed.ncbi.nlm.nih.gov/25037855
Autor:
Osuna‐Gómez, Rubén1 (AUTHOR), Barril, Silvia2,3 (AUTHOR), Mulet, Maria1 (AUTHOR), Zamora Atenza, Carlos1 (AUTHOR), Millan‐Billi, Paloma3,4 (AUTHOR), Pardessus, Ana3 (AUTHOR), Brough, Douglas E.5 (AUTHOR), Sabzevari, Helen5 (AUTHOR), Semnani, Roshanak T.5 (AUTHOR), Castillo, Diego1,2,3 (AUTHOR), Vidal, Silvia1 (AUTHOR) svidal@santpau.cat
Publikováno v:
Immunology. Apr2023, Vol. 168 Issue 4, p610-621. 12p.
Autor:
Alserawan, Leticia1 (AUTHOR), Anguera, Geòrgia2 (AUTHOR), Zamora Atenza, Carlos1 (AUTHOR), Serra López, Jorgina2 (AUTHOR), Martínez-Martínez, Laura3 (AUTHOR), Riudavets Melià, Mariona2 (AUTHOR), Sullivan, Ivana2 (AUTHOR), Barba Joaquin, Andrés2 (AUTHOR), Majem Tarruella, Margarita2 (AUTHOR), Vidal, Silvia1 (AUTHOR) svidal@santpau.cat
Publikováno v:
International Journal of Molecular Sciences. Oct2022, Vol. 23 Issue 20, p12641-N.PAG. 13p.
Autor:
Zamora Atenza, Carlos, Anguera, Geòrgia, Riudavets Melià, Mariona, Alserawan De Lamo, Letícia, Sullivan, Ivana, Barba Joaquin, Andrés, Serra Lopez, Jorgina, Ortiz, M. Angels, Mulet, Maria, Vidal, Sílvia, Majem, Margarita
Publikováno v:
Cancer Immunology, Immunotherapy; Aug2022, Vol. 71 Issue 8, p1823-1835, 13p
Autor:
Cantó, Elisabet1 ecanto@santpau.cat, Garcia Planella, Esther2, Zamora-Atenza, Carlos1, Nieto, Juan Camilo1, Gordillo, Jordi2, Ortiz, Ma Angels1, Metón, Isidoro3, Serrano, Elena4, Vegas, Esteban5, García-Bosch, Orlando6, Juárez, Cándido7,8, Vidal, Sílvia1,8
Publikováno v:
PLoS ONE. Apr2014, Vol. 9 Issue 4, p1-10. 10p.